# IBB (iShares Biotechnology ETF) iShares · Thematic ETFs · data as of Oct 28, 2026 Promise check: Not measured. Its theme exposure is measured once ETFIQ defines its theme company by company. https://etfiq.com/promise-index/ Over the year to Oct 28, 2026, IBB returned 37.5%. ## Key facts - IBB, already in the S&P 500: 40.2%, as of Oct 27, 2026. - IBB, active share vs the S&P 500: 99.0%, as of Oct 27, 2026. - IBB, top ten holdings: 50.5%, as of Oct 27, 2026. - IBB, total return, 1 year: +37.5%, as of Oct 28, 2026. - IBB, 12-month yield, capital gains included, on its starting price: 0.2%, as of Oct 28, 2026. - IBB, last payment (paid quarterly), ex-date Sep 15, 2026: $0.0112, as of Sep 15, 2026. - IBB, net assets: $11.0bn (the issuer’s own daily fund list, as of Oct 27, 2026). - IBB, expense ratio: 0.44% (485BPOS XBRL, Jul 27, 2026). ## IBB over each window to Oct 28, 2026 | Window | Total return | S&P 500 (SPY) | | --- | --- | --- | | 1 month | +2.7% | +0.9% | | 3 months | +14.8% | +6.1% | | 6 months | +30.8% | +9.1% | | Year to date | +28.3% | +14.1% | | 1 year | +37.5% | +13.6% | | 3 years | +93.9% | +95.0% | | 5 years | +37.3% | +79.8% | | 10 years | +155.6% | +325.8% | | Since launch | +555.1% | +817.5% | | Since launch, annualised | +7.6% | – | ## IBB key stats - 52-week high, daily closes to Oct 28, 2026: $216.96 on Aug 19, 2026 (computed by ETFIQ from Tiingo daily prices) - 52-week low, daily closes to Oct 28, 2026: $156.08 on Nov 4, 2025 (computed by ETFIQ from Tiingo daily prices) - Close on Oct 28, 2026, within that range: $216.35, 99% of the way from the low to the high (computed by ETFIQ from Tiingo daily prices) - Holdings: 245 - Top ten holdings weight: 50.5% ## IBB trading - Not scored. - Premium to NAV at the Oct 27 close: +0.07%; 95% of days within ±0.08%. - The full trading page: https://etfiq.com/funds/ibb/trading/ ## Every published field | Field | Value | Source | | --- | --- | --- | | Theme | Biotech | ETFIQ, editorial | | First traded | Feb 12, 2001 | ETFIQ | | Already in the S&P 500, by weight | 40.2% | ETFIQ | | Outside the S&P 500, by weight | 60% | ETFIQ | | Active share vs the S&P 500 | 99.0% | ETFIQ | | Already in the Nasdaq-100, by weight | 33.5% | ETFIQ | | Active share vs the Nasdaq-100 | 97.4% | ETFIQ | | Top ten holdings weight | 50.5% | ETFIQ | | Holdings | 245 | ETFIQ | | Holdings published for | Oct 27, 2026 | the issuer’s daily file | | Holdings as of the close of | Oct 27, 2026 | the issuer’s daily file | | Top holdings | GILEAD SCIENCES 8.6%, AMGEN INC 8.2%, VERTEX PHARMACEUTICALS 7.5%, REGENERON PHARMACEUTICALS 5.6%, MODERNA 5.3%, NATERA 3.9%, ARGENX SE ADR 3.4%, ILLUMINA INC 2.9%, BIOGEN 2.6%, REVOLUTION MEDICINES 2.5% | ETFIQ | | Net assets | $11.0bn | the issuer’s own daily fund list, as of Oct 27, 2026 | | Benchmark | Its own holdings, as of Oct 27, 2026; its shareholder report compares it with the MSCI USA Index, but its daily returns fit PBUS's at R-squared 0.212 over the year to Oct 28, 2026 (251 days), under the 0.35 it needs to return to it | ETFIQ, from its filings | | Below its all-time high | −0.3% | ETFIQ | | Expense ratio | 0.44% | 485BPOS XBRL, Jul 27, 2026 | | Fee for the part that differs from the S&P 500, active expense ratio | 0.44% | ETFIQ | | Closest funds by holdings overlap | IBBQ 85%, BBH 64%, FBT 44%, XBI 43%, PBE 43% | ETFIQ | ## Money in and out, to Oct 23, 2026 | Window | Dates | Net flow | | --- | --- | --- | | 1 week | Oct 21, 2026 to Oct 23, 2026 | +$11.0m | | 1 month | Sep 28, 2026 to Oct 23, 2026 | +$199m | | 3 months | Jul 28, 2026 to Oct 23, 2026 | +$427m | | Year to date | Jan 2, 2026 to Oct 23, 2026 | +$538m | | 1 year | Oct 28, 2025 to Oct 23, 2026 | +$1.8bn | Computed by ETFIQ from the change in shares outstanding times the previous day’s NAV. Every day and month: . Method: https://etfiq.com/methodology/flows ## Questions ### How much of IBB is in S&P 500 companies? By its holdings published by its issuer for Oct 27, 2026, 40% of IBB by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different. ### What does IBB hold? 245 positions as published by its issuer for Oct 27, 2026, with the top ten at 50% of the fund. The largest are GILEAD SCIENCES at 8.6%, AMGEN INC at 8.2%, VERTEX PHARMACEUTICALS at 7.5%. ### Has IBB beaten the S&P 500? Over the year to Oct 28, 2026 IBB returned +37.5% with distributions reinvested, against +13.6% for the S&P 500, so it finished ahead of the index by 23.9 points. ### What does IBB cost? The prospectus expense ratio is 0.44% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.44%. ## Cite this page ETFIQ, IBB, thematic ETFs, data as of Oct 28, 2026. https://etfiq.com/funds/ibb Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms. The underlying files are at . HTML: https://etfiq.com/funds/ibb · JSON: https://etfiq.com/funds/ibb.json